B Reisberg

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: management and treatment import
    Barry Reisberg
    Alzheimer's Disease Education and Resources Program, New York University School of Medicine, New York, USA
    Am J Alzheimers Dis Other Demen 17:202-12. 2002
  2. ncbi Global measures: utility in defining and measuring treatment response in dementia
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, Silberstein Aging and Dementia Research Center, New York, NY 10016, USA
    Int Psychogeriatr 19:421-56. 2007
  3. ncbi Staging: relevance for trial design in vascular burden of the brain
    Barry Reisberg
    William and Sylvia Silberstein Aging and Dementia Research Center, New York University School of Medicine, NY 10016, USA
    Int Psychogeriatr 15:231-9. 2003
  4. ncbi A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Arch Neurol 63:49-54. 2006
  5. ncbi Diagnostic criteria in dementia: a comparison of current criteria, research challenges, and implications for DSM-V
    Barry Reisberg
    Department of Psychiatry and Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY 10016, USA
    J Geriatr Psychiatry Neurol 19:137-46. 2006
  6. ncbi Mild cognitive impairment (MCI): a historical perspective
    Barry Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 20:18-31. 2008
  7. ncbi Memantine in moderate-to-severe Alzheimer's disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    N Engl J Med 348:1333-41. 2003
  8. ncbi The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease
    Barry Reisberg
    Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 4:S98-S108. 2008
  9. ncbi The Alzheimer's disease activities of daily living international scale (ADL-IS)
    B Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 13:163-81. 2001
  10. ncbi Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes
    B Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Eur Arch Psychiatry Clin Neurosci 249:28-36. 1999

Research Grants

  1. AGING AND DEMENTIA--LONGITUDINAL COURSE OF SUBGROUPS
    Barry Reisberg; Fiscal Year: 2002

Detail Information

Publications32

  1. ncbi Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: management and treatment import
    Barry Reisberg
    Alzheimer's Disease Education and Resources Program, New York University School of Medicine, New York, USA
    Am J Alzheimers Dis Other Demen 17:202-12. 2002
    ..A science of AD management can be formulated on the basis of the DA of the Alzheimer's patient, taking into consideration differences of AD from normal development as well as homologies...
  2. ncbi Global measures: utility in defining and measuring treatment response in dementia
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, Silberstein Aging and Dementia Research Center, New York, NY 10016, USA
    Int Psychogeriatr 19:421-56. 2007
    ..For Mild Cognitive Impairment (MCI), global severity scales already appear to be one modality for the sensitive assessment of change. The CIBIC-Plus procedures might also productively be applied in future MCI therapeutic trials...
  3. ncbi Staging: relevance for trial design in vascular burden of the brain
    Barry Reisberg
    William and Sylvia Silberstein Aging and Dementia Research Center, New York University School of Medicine, NY 10016, USA
    Int Psychogeriatr 15:231-9. 2003
    ..Although temporal and prognostic aspects have been studied for the Alzheimer's-related portions of this clinical staging continuum, they remain to be elucidated for cerebrovascular small vessel disease...
  4. ncbi A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Arch Neurol 63:49-54. 2006
    ..This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease...
  5. ncbi Diagnostic criteria in dementia: a comparison of current criteria, research challenges, and implications for DSM-V
    Barry Reisberg
    Department of Psychiatry and Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY 10016, USA
    J Geriatr Psychiatry Neurol 19:137-46. 2006
    ..quot; DSM-V should incorporate continuing advances in the neuroscience knowledge base and understanding of these disorders...
  6. ncbi Mild cognitive impairment (MCI): a historical perspective
    Barry Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 20:18-31. 2008
    ..Nevertheless, longitudinal and other studies indicate essential compatibility between GDS stage 3 MCI and Petersen's MCI duration and outcomes...
  7. ncbi Memantine in moderate-to-severe Alzheimer's disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    N Engl J Med 348:1333-41. 2003
    ..Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease...
  8. ncbi The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease
    Barry Reisberg
    Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 4:S98-S108. 2008
    ..Subjective cognitive impairment (SCI) has been a common, but poorly understood condition, frequently occurring in older persons...
  9. ncbi The Alzheimer's disease activities of daily living international scale (ADL-IS)
    B Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Int Psychogeriatr 13:163-81. 2001
    ..Despite this acknowledged importance, no clearly useful ADL instrument for cross-cultural application in pharmacologic trials in the early stages of AD had been available...
  10. ncbi Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes
    B Reisberg
    Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA
    Eur Arch Psychiatry Clin Neurosci 249:28-36. 1999
    ..Management strategies based upon retrogenesis have recently been proposed. Retrogenic pathophysiology also points to previously unexplored pharmacologic approaches to dementia prevention and treatment...
  11. ncbi Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment
    M J de Leon
    Department of Psychiatry, New York University School of Medicine New York, Center for Brain Health of the Silberstein Institute, NY 10016, USA
    Neurobiol Aging 27:394-401. 2006
    ..These results demonstrate that CSF biomarkers for AD contribute to the characterization of MCI...
  12. ncbi The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale
    S R Auer
    Aging and Dementia Research Center, New York University Medical Center, New York, USA
    Int Psychogeriatr 8:247-66. 1996
    ....
  13. ncbi Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability
    I M Monteiro
    Aging and Dementia Research Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Eur Psychiatry 16:5s-24s. 2001
    ..69 to 0.98 for the seven symptom categories (p(s) < 0.001). For the BEHAVE-AD-FW total scores, the ICC was 0.91 (P < 0.001). These results indicate that the frequency-weighted component is a reliable addition to the BEHAVE-AD scale...
  14. ncbi Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET)
    M J de Leon
    Center for Brain Health, New York University School of Medicine, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 98:10966-71. 2001
    ..Further study is required to estimate individual risks and to determine the physiologic basis for METglu changes detected while cognition is normal...
  15. ncbi Towards a science of Alzheimer's disease management: a model based upon current knowledge of retrogenesis
    B Reisberg
    Zachary and Elizabeth M Fisher Alzheimer s Disease Education and Resources Program, New York University Medical Center, New York 10016, USA
    Int Psychogeriatr 11:7-23. 1999
    ..In AD, these processes may be termed "retrogenesis." The relevance of the retrogenesis model for AD management is explored...
  16. ncbi Outcome over seven years of healthy adults with and without subjective cognitive impairment
    Barry Reisberg
    Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, USA
    Alzheimers Dement 6:11-24. 2010
    ....
  17. ncbi MRI and CSF studies in the early diagnosis of Alzheimer's disease
    M J de Leon
    Center for Brain Health, New York University School of Medicine, NY
    J Intern Med 256:205-23. 2004
    ..The interim results also suggest that a panel of CSF biomarkers can provide measures both sensitive to longitudinal change as well as measures that lend specificity to the AD diagnosis...
  18. ncbi Subjective memory complaints: presence, severity and future outcome in normal older subjects
    Lidia Glodzik-Sobanska
    Center for Brain Health, New York University School of Medicine, New York, NY 10016, USA
    Dement Geriatr Cogn Disord 24:177-84. 2007
    ..Subjective memory complaint (SMC) in normal individuals may predict future cognitive decline. The goal of this study was to examine whether the probability of decline increases with growing intensity of complaint...
  19. ncbi FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease
    Lisa Mosconi
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Eur J Nucl Med Mol Imaging 36:811-22. 2009
    ....
  20. ncbi Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline
    Susan De Santi
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neuropsychology 22:469-84. 2008
    ..These findings indicate that Robust norms improve identification of healthy individuals who will decline and may be useful for selecting at-risk participants for research studies and early interventions...
  21. ncbi Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging
    L S Prichep
    Brain Research Laboratories, Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 27:471-81. 2006
    ..These data indicate high sensitivity and specificity for baseline QEEG as a differential predictor of future cognitive state in normal, subjectively impaired elderly...
  22. ncbi Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration
    Jerzy Wegiel
    Department of Developmental Neurobiology, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, 10314, USA
    Acta Neuropathol 113:389-402. 2007
    ....
  23. ncbi Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study
    Steven J Choi
    Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Geriatr Psychiatry Neurol 18:12-9. 2005
    ....
  24. ncbi An entorhinal cortex sulcal pattern is associated with Alzheimer's disease
    Jiong Zhan
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    Hum Brain Mapp 30:874-82. 2009
    ..We classified the lateral EC sulcal boundary as either a rhinal or collateral pattern and tested the hypotheses that the rhinal pattern was (1) more common in AD and (2) associated with a smaller EC size...
  25. ncbi Vascular cognitive impairment
    John T O'Brien
    Institute for Aging and Health, Newcastle General Hospital, Newcastle upon Tyne, UK
    Lancet Neurol 2:89-98. 2003
    ..Clinical trials in vascular cognitive impairment are in their infancy but support the value of therapeutic interventions for symptomatic treatment...
  26. ncbi Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease
    Barry Reisberg
    Int Psychogeriatr 20:1-16. 2008
  27. ncbi ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Alzheimer Dis Assoc Disord 20:S124-38. 2006
    ..An important consideration was whether global assessments are specific and sensitive measures of change during a prevention trial...
  28. ncbi Mild cognitive impairment
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Lancet 367:1262-70. 2006
    ..Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia...
  29. ncbi Vascular burden of the brain
    Barry Reisberg
    Int Psychogeriatr 15:7-10. 2003
  30. ncbi A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium
    Zaven S Khachaturian
    Alzheimers Dement 4:156-63. 2008
  31. ncbi Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain
    Jerzy Wegiel
    Department of Developmental Neurobiology, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314, USA
    Brain Res 1010:69-80. 2004
    ..Differences in the topography and the amount of Mnb/Dyrk1A in neurons, astrocytes, and ependymal and endothelial cells appear to reflect cell type- and brain structure-specific patterns in trafficking and utilization of Mnb/Dyrk1A...
  32. ncbi Alzheimer's disease and medical disease conditions: a prospective cohort study
    Istvan Boksay
    J Am Geriatr Soc 53:2235-6. 2005

Research Grants8

  1. AGING AND DEMENTIA--LONGITUDINAL COURSE OF SUBGROUPS
    Barry Reisberg; Fiscal Year: 2002
    ..Collectively, these cohorts include over 1300 persons. The comprehensive evaluations include behavioral, mental status, neuropsychologic, neurologic, neuroimaging, electrophysiologic, and postmortem studies. ..